Delivery Order N0018914DE006-0003

This federal contract award to Regenesis Biomedical Inc. (Regenesis) was issued by the U.S. Department of Veterans Affairs (VA) for the Provant Therapy System, a non-invasive regenerative medicine product developed and patented by Regenesis. The $4,820.98 firm-fixed-price purchase order contract has an ultimate completion date of November 14, 2011. Regenesis, a for-profit manufacturer, is the prime contractor and will directly provide the Provant Therapy System to the VA under this contract,...

This federal contract award is for the Department of Veterans Affairs (VA) to procure the Provant Therapy System and associated rental services from Regenesis Biomedical Inc. The $3,645.14 firm fixed-price purchase order was issued under Regenesis Biomedical's GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is Regenesis Biomedical's patented non-invasive regenerative medicine product, indicated for palliative treatment of post-operative pain and...

The federal contract award VA580W15967 was granted to Regenesis Biomedical Inc., a for-profit medical technology company focused on regenerative medicine products. The $4,820.98 firm fixed-price contract was awarded by the Department of Veterans Affairs (VA) and is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive product indicated for the palliative treatment of post-operative pain and edema. The contract does not have a set-aside designation....

This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and a completion date of June 24, 2011. There is no set-aside designation...

This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...

This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The $7,142.85 firm fixed-price purchase order is for the Provant Therapy System, a non-invasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract does not use a set-aside designation. The award was made under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies....

This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $3,645.14 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract has an ultimate completion date of March 25, 2011. This award was made against Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A...

This federal contract award is for the provision of the Provant Therapy System by Regenesis Biomedical Inc. to the Department of Veterans Affairs (VA). The contract, valued at $7,145.55, is a firm-fixed-price purchase order awarded on August 19, 2011 with a completion date of September 18, 2011. The Provant Therapy System is a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. Regenesis Biomedical, a for-profit manufacturer, has...

The Department of the Navy Naval Sea Systems Command (DOD - Navy) awarded a $556,670 firm fixed price delivery order contract to Evoqua Water Technologies LLC, doing business as Usfilter Corp, to provide regeneration services. The contract has a period of performance from April 5, 2022 to April 5, 2023 and will be performed in Portsmouth, Virginia. Evoqua Water Technologies LLC will utilize regeneration to treat and recycle used materials for the Navy, helping to support fleet operations from...

This is a $3,645.14 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a noninvasive regenerative medicine product. The contract is not set-aside and was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is indicated for palliative treatment of post-operative pain and edema, and Regenesis Biomedical appears to be the...